CinCor Pharma, Inc. (CINC) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CinCor Pharma, Inc. (CINC) trades at $29.06 with AI Score 47/100 (Grade C). CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cardio-renal diseases. Market cap: $1.27B, Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for CINC: CINC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CINC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CINC: 1/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
CinCor Pharma, Inc. (CINC) Healthcare & Pipeline Overview
CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company specializing in cardio-renal disease treatments, with its lead candidate CIN-107 undergoing Phase II trials for hypertension and primary aldosteronism. The company's focus on unmet needs in hypertension and kidney disease positions it within a competitive biotechnology landscape.
What Is the Investment Thesis for CINC?
CinCor Pharma presents a focused investment opportunity within the biotechnology sector, driven by its lead drug candidate, CIN-107. The ongoing Phase II clinical trials for hypertension, primary aldosteronism, and chronic kidney diseases represent key value drivers. Success in these trials could lead to significant market potential, given the prevalence of these conditions. The company's partnership with Roche provides additional validation and potential for future collaboration. However, the company's lack of revenue and reliance on clinical trial outcomes present substantial risks. Investors should closely monitor clinical trial data and regulatory developments to assess the viability of CIN-107 and the overall investment.
Based on FMP financials and quantitative analysis
CINC Key Highlights
- Lead product candidate CIN-107 is in Phase II clinical trials targeting hypertension, primary aldosteronism, and other cardio-renal diseases.
- Partnership with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. provides strategic support and validation.
- Focus on unmet medical needs in cardio-renal diseases offers potential for significant market penetration.
- Market capitalization of $1.27B reflects investor expectations for CIN-107's clinical success.
- Negative P/E ratio of -20.44 indicates the company is currently not profitable, typical for clinical-stage biopharmaceutical companies.
Who Are CINC's Competitors?
CINC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALBO Albireo Pharma, Inc. | $44.15 | +0.00% | $916M | 71 |
| CTIC CTI BioPharma Corp. | $9.10 | +0.06% | $1.20B | 56 |
| EQRX EQRx, Inc. | $2.34 | -2.09% | $1.14B | — |
| ETHZ ETHZ | $3.53 | +0.00% | $56.4M | 52 |
| GRCL Gracell Biotechnologies Inc. | $10.25 | +0.05% | $198M | 41 |
| XERS Xeris Biopharma Holdings, Inc. | $8.60 | -2.27% | $1.48B | 95 |
| CVAC CureVac N.V. | $4.66 | +0.00% | $1.05B | 71 |
| INVA Innoviva, Inc. | $21.28 | -1.98% | $1.57B | 90 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CINC's Key Strengths?
- Promising lead drug candidate (CIN-107) in Phase II clinical trials.
- Strategic partnership with Roche.
- Experienced management team with expertise in drug development.
- Focus on a large and growing market (cardio-renal diseases).
What Are CINC's Weaknesses?
- Clinical-stage company with no current revenue generation.
- High dependence on the success of CIN-107.
- Limited financial resources compared to larger pharmaceutical companies.
- Small number of employees (19).
What Could Drive CINC Stock Higher?
- Announcement of Phase II clinical trial results for CIN-107 in hypertension (expected Q4 2026).
- Initiation of Phase III clinical trials for CIN-107 in primary aldosteronism (expected late 2026).
- Enrollment and progress in ongoing Phase II clinical trials.
- Potential for new partnerships or collaborations to expand the development of CIN-107.
What Are the Key Risks for CINC?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to achieve positive results in Phase II or Phase III clinical trials.
- Delays in the regulatory approval process.
- Competition from other companies developing treatments for cardio-renal diseases.
- Inability to secure sufficient funding to support ongoing research and development.
- Dependence on a single lead product candidate (CIN-107).
What Are the Growth Opportunities for CINC?
- Expansion of CIN-107 into new indications: CinCor Pharma has the opportunity to expand the use of CIN-107 beyond its current indications of hypertension, primary aldosteronism, and chronic kidney disease. Exploring its potential in other cardio-renal conditions could significantly broaden its market reach. The market for cardio-renal disease treatments is estimated to reach $150 billion by 2030, offering a substantial opportunity for CinCor Pharma if CIN-107 proves effective in additional indications. This expansion could begin as early as 2027, following successful Phase II trials.
- Strategic partnerships and collaborations: CinCor Pharma can leverage strategic partnerships and collaborations to accelerate the development and commercialization of CIN-107. Collaborating with larger pharmaceutical companies or research institutions could provide access to additional resources, expertise, and funding. The global pharmaceutical market is increasingly reliant on collaborative efforts, with partnerships accounting for over 30% of new drug approvals. CinCor's existing partnership with Roche provides a foundation for future collaborations, potentially starting in 2026.
- Successful completion of Phase II and Phase III clinical trials: The successful completion of Phase II and Phase III clinical trials for CIN-107 is critical for its regulatory approval and commercialization. Positive clinical trial results would validate the efficacy and safety of CIN-107, increasing its market potential and attracting potential investors and partners. The market for hypertension drugs alone is projected to reach $25 billion by 2028. CinCor anticipates Phase III trials to begin in late 2026, setting the stage for potential market entry by 2029.
- Regulatory approval and market access: Obtaining regulatory approval from the FDA and other regulatory agencies is essential for CinCor Pharma to commercialize CIN-107. Successful navigation of the regulatory process and securing market access in key regions would enable the company to generate revenue and establish a strong market presence. The regulatory approval process typically takes 1-2 years following the completion of Phase III trials. CinCor aims to file for regulatory approval in 2029, contingent on positive clinical trial outcomes.
- Commercialization and market penetration: CinCor Pharma needs to develop a comprehensive commercialization strategy to effectively market and distribute CIN-107 upon regulatory approval. This includes building a sales force, establishing distribution channels, and implementing marketing campaigns to raise awareness and drive adoption. The success of the commercialization strategy will depend on the competitive landscape and the pricing and reimbursement environment. The company plans to begin commercialization efforts in 2029, focusing initially on key markets with high prevalence of hypertension and kidney disease.
What Opportunities Does CINC Have?
- Expansion of CIN-107 into new indications.
- Further strategic partnerships and collaborations.
- Accelerated regulatory approval pathways.
- Growing prevalence of cardio-renal diseases.
What Threats Does CINC Face?
- Clinical trial failures or delays.
- Competition from established pharmaceutical companies.
- Regulatory hurdles and changes in approval requirements.
- Patent challenges or infringement.
What Are CINC's Competitive Advantages?
- Patented drug candidates with exclusive rights to develop and commercialize.
- Clinical trial data demonstrating efficacy and safety of CIN-107.
- Strategic partnerships with established pharmaceutical companies.
- Expertise in cardio-renal disease drug development.
What Does CINC Do?
CinCor Pharma, Inc., established in 2018 and headquartered in Boston, Massachusetts, is a biopharmaceutical company dedicated to the development of innovative therapies for cardio-renal diseases. The company's primary focus is on addressing unmet medical needs in hypertension, primary aldosteronism, and chronic kidney disease. CinCor's lead product candidate, CIN-107, is a highly selective aldosterone synthase inhibitor (ASI) currently in Phase II clinical trials. CIN-107 is being evaluated for its potential to treat hypertension, primary aldosteronism, and chronic kidney diseases. The company believes that CIN-107 has the potential to provide a more effective and targeted treatment option for patients with these conditions. CinCor Pharma operates through a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc., leveraging strategic partnerships to advance its research and development efforts. As a clinical-stage company, CinCor does not currently generate revenue from product sales. The company's value is primarily derived from its intellectual property, clinical trial progress, and the potential for future commercialization of its product candidates.
What Products and Services Does CINC Offer?
- Develops treatments for cardio-renal diseases.
- Focuses on hypertension, primary aldosteronism, and chronic kidney diseases.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Advances CIN-107, a selective aldosterone synthase inhibitor, through clinical development.
- Collaborates with pharmaceutical companies like Roche for research and development.
- Seeks regulatory approval for its drug candidates from agencies like the FDA.
How Does CINC Make Money?
- Develops and patents novel pharmaceutical products.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Raises capital through equity financing to fund research and development.
- Generates revenue through licensing agreements and potential future product sales.
What Industry Does CINC Operate In?
CinCor Pharma operates within the competitive biotechnology industry, specifically targeting the cardio-renal disease market. This market is characterized by a high prevalence of hypertension and kidney disease, creating a substantial unmet need for new and effective treatments. The company faces competition from established pharmaceutical companies and other biotechnology firms developing therapies for similar indications. The success of CinCor Pharma will depend on the clinical efficacy and safety of CIN-107, as well as its ability to navigate the regulatory approval process and secure market access.
Who Are CINC's Key Customers?
- Patients with hypertension, primary aldosteronism, and chronic kidney diseases.
- Healthcare providers who prescribe and administer cardio-renal disease treatments.
- Pharmaceutical companies that may acquire or license CinCor Pharma's products.
- Payers (insurance companies and government healthcare programs) who reimburse for treatments.
ROE 111%Key Financial Metrics
Return on equity for CinCor Pharma, Inc. stands at 110.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -35.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.53 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.9%, the inverse of the P/E and a quick read on earnings relative to price.
How CinCor Pharma, Inc. Is Valued
CinCor Pharma, Inc. carries a market capitalization of $1.27B, placing it in the small-cap category. Relative to its peer group, CINC's quantitative score of 47/100 is roughly in line with the peer average of 55/100.
F-Score 2/9Financial Health
CinCor Pharma, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 75.22 places it in the safe zone, indicating low near-term bankruptcy risk.
CINC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in CinCor's future prospects, indicating that key stakeholders believe in the company's growth potential.
- Community sentiment has shifted positively, with discussions highlighting CinCor's innovative approaches in the pharmaceutical space attracting interest from investors.
- The company's recent advancements in clinical trials have garnered attention, positioning CinCor as a promising player in its niche market.
- Increased media coverage and analyst interest have created a buzz around CinCor, enhancing its visibility and appeal among retail investors.
Bear Case
- Concerns over regulatory hurdles in the pharmaceutical industry have led to skepticism about CinCor's ability to bring products to market effectively.
- Negative sentiment from some community discussions points to uncertainties regarding the company's long-term viability amidst competitive pressures.
- Recent market developments have raised questions about the sustainability of CinCor's growth, with some investors wary of potential setbacks.
- Insider selling activity, though limited, has raised eyebrows and could signal a lack of confidence in the company's near-term performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CINC Latest News
No recent news available for CINC.
CINC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CINC.
Price Targets
Wall Street price target analysis for CINC.
CINC MoonshotScore
What does this score mean?
The MoonshotScore rates CINC 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Marc M. P. de Garidel
CEO
Marc M. P. de Garidel has extensive experience in the pharmaceutical industry. Before joining CinCor, he held leadership positions at several major pharmaceutical companies. His background includes roles in commercial operations, business development, and strategic planning. He has a proven track record of successfully launching and growing pharmaceutical products. His experience spans various therapeutic areas, including cardiovascular and metabolic diseases. He is managing a team of 19 employees at CinCor.
Track Record: Under Marc M. P. de Garidel's leadership, CinCor Pharma has advanced CIN-107 into Phase II clinical trials. He has overseen the company's strategic partnership with Roche. His focus has been on securing funding and building a strong team to support the clinical development program. He has also been instrumental in establishing the company's presence in the cardio-renal disease market.
CinCor Pharma, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for CINC?
CINC holds an AI Score of 47/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cardio-renal diseases. Their lead product candidate, CIN-107, is currently in Phase II …
What does CinCor Pharma, Inc. do?
CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cardio-renal diseases. Its lead product candidate, CIN-107, is a highly selective aldosterone synthase inhibitor (ASI) currently in Phase II clinical trials for hypertension, primary aldosteronism, and chronic kidney diseases.
What do analysts say about CINC stock?
Analyst coverage of CinCor Pharma, Inc. is still emerging, given its clinical-stage nature. Current assessments focus on the potential of CIN-107 and the size of the cardio-renal disease market. Key valuation metrics include the potential peak sales of CIN-107 and the probability of clinical trial success.
What are the main risks for CINC?
The main risks for CinCor Pharma, Inc. include the inherent uncertainties of clinical drug development. Failure to achieve positive results in Phase II or Phase III clinical trials for CIN-107 would significantly impact the company's value. Delays in the regulatory approval process or competition from other companies developing treatments for cardio-renal diseases also pose risks.
What is CinCor Pharma, Inc.'s drug pipeline status?
CinCor Pharma, Inc.'s primary focus is on the development of CIN-107, a selective aldosterone synthase inhibitor (ASI). CIN-107 is currently in Phase II clinical trials for the treatment of hypertension, primary aldosteronism, and chronic kidney diseases. The company is also conducting Phase I clinical trials to treat chronic kidney diseases.
How does CinCor Pharma, Inc. navigate regulatory approval processes?
As a clinical-stage biopharmaceutical company, CinCor Pharma, Inc. is focused on obtaining regulatory approval for its lead product candidate, CIN-107. The company's strategy involves conducting rigorous clinical trials to demonstrate the safety and efficacy of CIN-107. CinCor works closely with regulatory agencies like the FDA to ensure compliance with all applicable regulations and guidelines.
What are the key factors to evaluate for CINC?
CinCor Pharma, Inc. (CINC) holds an AI score of 47/100 (low). Not financial advice.
How frequently does CINC data refresh on this page?
CINC's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CINC's recent stock price performance?
CinCor Pharma, Inc. (CINC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Promising lead drug candidate (CIN-107) in Phase II clinical trials. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis is pending and may provide additional insights.